The Impact of Fruit Juice, Fruit Juice With Pomace, or Whole Fruit on Glycemic Response
NCT ID: NCT04369716
Last Updated: 2020-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2017-10-09
2017-12-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Added Fruit Pomace Fiber, Juice, and Whole Fruit on Postprandial Glycemia
NCT04182971
Postprandial Glycemia in Orange Products
NCT03685201
Postprandial Glycemia in Apple Products
NCT03846986
Effect of Orange Pomace Fiber on Glycemic Response
NCT02962375
Acute Effects of Fruit Juices Consumption on Postprandial Glycemic Responses and Satiety
NCT06163937
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
24 hr diet records are reviewed each test day to verify food and drink consistency and a diet containing at least 150 g of carbohydrate. Subjects arrive fasted (10-14 h, water only), are asked to maintain adequate hydration; and refrain from vigorous physical activity (24 h), alcohol consumption (24 h), and tobacco products (for at least 1 h).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Whole fruit 1
Oranges
Whole oranges
Navel oranges (227 g total)
Whole fruit 2
Apples
Whole Apples
Red Delicious apple with skin (230 g)
Juice 1 + pomace
Orange Juice + orange pomace
Orange juice + orange pomace
Orange Juice (149 g) + orange pomace (100g) \[40% pomace by weight\]
Juice 2 + pomace
Apple Juice + apple pomace
Apple juice + apple pomace
Apple Juice (129 g) + apple pomace (106 g) \[45% pomace by weight\]
Juice 1 alone
Orange Juice
Orange juice
Orange Juice (250 g)
Juice 2 alone
Apple Juice
Apple juice
Apple Juice (235 g)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Whole oranges
Navel oranges (227 g total)
Whole Apples
Red Delicious apple with skin (230 g)
Orange juice + orange pomace
Orange Juice (149 g) + orange pomace (100g) \[40% pomace by weight\]
Apple juice + apple pomace
Apple Juice (129 g) + apple pomace (106 g) \[45% pomace by weight\]
Orange juice
Orange Juice (250 g)
Apple juice
Apple Juice (235 g)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has a BMI of 18.5 to 29.9 kg/m2, inclusive, at Visit 1.
3. Subject has a rating of 7 to 10 on the Vein Access Scale at Visit 1.
4. If a smoker, subject has no plans to change smoking habits during the study period and is able to abstain from tobacco products at least 1 h prior to and during each test visit
5. Subject is on a stable dose of vitamins, minerals, and other supplements throughout the trial and is willing to maintain the current use throughout the trial. On test days, subject agrees not to take any vitamins, minerals, or other dietary supplements until dismissal from the clinic. Failure to comply will result in a rescheduled test visit.
6. If a female on oral contraceptives, the subject must be on a stable dose of oral contraceptives \[defined as same dose for the past 90 d
7. If applicable, subject must be on a stable dose of.osteoporosis medication, anti-hypertensive medication, aspirin, and/or thyroid medication.
8. Subject is normally active and judged by the Investigator to be in general good health on the basis of medical history.
9. Subject is willing to maintain physical activity patterns, body weight, and habitual diet throughout the trial.
10. Subject is willing to abstain from alcohol consumption and avoid vigorous physical activity for 24 h prior to and during test visits.
11. Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the Investigators.
12. Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history and routine laboratory test results.
Exclusion Criteria
2. Subject has the presence of a gastrointestinal disease or condition that could potentially interfere with absorption of the study product (including but not limited to inflammatory bowel diseases, ulcers), including history of gastrointestinal surgery (e.g., for weight reduction).
3. Subject has a history or presence of clinically important endocrine, cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary (including uncontrolled asthma), hepatic, renal, hematologic, immunologic, neurologic (such as Alzheimer's or Parkinson's disease), or biliary disorders, in the opinion of the Clinical Investigator.
4. Subject has a history of bariatric surgery.
5. Subject has extreme dietary habits (e.g., Atkins diet, very high protein, vegetarian), in the opinion of the Clinical Investigator.
6. Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg) as defined by the blood pressure measured at Visit 1. One retest will be allowed.
7. Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
8. Subject has experienced any major trauma or any other surgical event within three months
9. Subject has a known allergy, intolerances, or sensitivity to any of the ingredients in the study products.
10. Subject has had a weight loss or gain \>4.5 kg in the 3 months prior to Visit 1.
11. Subject has any signs or symptoms of an active infection of clinical relevance (e.g., urinary tract or respiratory) within 5 d prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved (at the discretion of the Investigator) and any treatment (e.g., antibiotic therapy) has been completed at least 5 d prior to testing.
12. Subject has a recent history of (within 12 months of Visit 1) or strong potential for alcohol or substance abuse. Alcohol abuse define as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).
13. Subject has used medications known to influence carbohydrate metabolism, including, but not limited to, protease inhibitors, antipsychotics, adrenergic receptor blockers, diuretics, anti-diabetic agents, and systemic corticosteroids, within 30 d of Visit 1.
14. Subject has used weight-loss drugs (including over-the-counter medications and/or supplements) or programs within 30 d prior to Visit 1.
15. Subject is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded in the source documentation.
16. Subject has been exposed to any non-registered drug product within 30 days prior to Visit 1.
17. Subject has a condition the Clinical Investigator believes would interfere with his ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PepsiCo Global R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrea Lawless, MD
Role: PRINCIPAL_INVESTIGATOR
Biofortis Innovation Services
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BioFortis Innovation Services
Addison, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEP-1709
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.